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The Mediator is an evolutionarily conserved, multi-subunit complex that regulates multiple steps of transcription. Mediator activity is
regulated by the reversible association of a four-subunit module comprising CDK8 or CDK19 kinases, together with cyclin C, MED12 or
MED12L, and MED13 or MED13L. Mutations inMED12,MED13, andMED13L were previously identified in syndromic developmental
disorders with overlapping phenotypes. Here, we report CDK8mutations (located at 13q12.13) that cause a phenotypically related dis-
order. Using whole-exome or whole-genome sequencing, and by international collaboration, we identified eight different heterozygous
missense CDK8 substitutions, including 10 shown to have arisen de novo, in 12 unrelated subjects; a recurrent mutation, c.185C>T
(p.Ser62Leu), was present in five individuals. All predicted substitutions localize to the ATP-binding pocket of the kinase domain.
Affected individuals have overlapping phenotypes characterized by hypotonia, mild to moderate intellectual disability, behavioral dis-
orders, and variable facial dysmorphism. Congenital heart disease occurred in six subjects; additional features present in multiple indi-
viduals included agenesis of the corpus callosum, ano-rectal malformations, seizures, and hearing or visual impairments. To evaluate the
functional impact of the mutations, we measured phosphorylation at STAT1-Ser727, a known CDK8 substrate, in a CDK8 and CDK19
CRISPR double-knockout cell line transfected with wild-type (WT) or mutant CDK8 constructs. These experiments demonstrated a
reduction in STAT1 phosphorylation by all mutants, in most cases to a similar extent as in a kinase-dead control. We conclude that
missense mutations in CDK8 cause a developmental disorder that has phenotypic similarity to syndromes associated with mutations
in other subunits of the Mediator kinase module, indicating probable overlap in pathogenic mechanisms.The Mediator complex is a large, multi-subunit assembly
encoded by 26 genes in humans, and it regulates gene
expression in all eukaryotes. The core function of the
Mediator is to communicate developmental and physio-
logical signals from DNA-bound transcription factors to
RNA polymerase II (the enzyme responsible for the tran-
scription of all protein-coding andmost non-coding genes)
by contacting the pre-initiation complex.1,2 Regulation of
Mediator activity is, in part, achieved by the reversible
association of a four-subunit kinase module (hereafter
referred to as the ‘‘Module’’) comprising cyclin C (encoded
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MED12L, and MED13L (Figure 1). Many targets of phos-
phorylation by CDK8 have been identified.4 These include
not only the core Mediator-RNA-polymerase-II complex
(Module components [CDK8, cyclin C, MED12, MED13,
and MED13L], other Mediator subunits [MED14 and
MED26], and the C-terminal domain of RNA polymerase
II) but also many other transcriptional regulators (for
example, tissue-specific and general transcription factors,
pause or release factors, chromatin-remodeling factors,
and histone H3; reviewed by Jeronimo and Robert).2 Mir-
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Figure 1. Simplified Illustration of the
Mediator Complex and the RNA Pol II
Machinery at the Promoter of a Hypothet-
ical Gene
The CDK8 or CDK19 kinase Module
(orange) reversibly binds the Mediator
complex to regulate its activity. The Medi-
ator complex (head in blue, middle in
green, and tail in purple; additional sub-
units in light gray) bridges between gene-
specific activators (dark gray) that are
bound to regulatory elements (RE) and
general transcription machinery that com-
prises the RNA pol II (brown) and general
transcription factors (yellow). The DNA
molecule cartoon was obtained from the
Servier Medical Art; the representation
was adapted from Larivie`re et al.3many tissue- and species-specific functions, ranging from
environmental responses in yeast to organogenesis and
development in the nematode worm, fruit fly, zebrafish,
and mouse.5
In humans, mutations in the genes (MED12, MED13,
and MED13L) encoding subunits of the Module have
been implicated in developmental disorders. Mutations
in the X-linked MED12 (MIM: 300188) cause at least
three different syndromes: Opitz-Kaveggia syndrome
(also known as FG syndrome; MIM: 305450), Lujan-Fryns
syndrome (MIM: 309520), and Ohdo syndrome (MIM:
300895). These syndromes have partly overlapping clinical
features, including multiple congenital defects, facial dys-
morphic features, hypotonia, behavioral problems, and
intellectual disability (ID).6 Mutations in MED13L (MIM:
608771) are associated with a syndromic form of ID
(MIM: 616789) characterized by facial dysmorphism, ID,
speech impairment, motor developmental delay with
muscular hypotonia, cardiac anomalies, and behavioral
difficulties.7,8 Recently, mutations in MED13 (MIM:
603808) have been reported as leading to a neurodevelop-
mental disorder characterized by ID and/or developmental
delay, including speech delay; additional features that were
present in two or more affected individuals included
autism spectrum disorder (ASD), attention deficit hyperac-
tivity disorder (ADHD), optic nerve abnormalities, Duane
anomaly, hypotonia, mild congenital heart abnormalities,
and dysmorphic features.9 Here, using whole-exome or
whole-genome sequencing and by international collabora-
tion, we report de novo mutations in CDK8, which has not
been previously associated with a congenital disorder, in
12 unrelated individuals with overlapping phenotypes.
The study was initiated as part of a whole-genome
sequencing (WGS)-based investigation of craniosynostosis
in the Netherlands after approval by the board of the med-
ical ethical committee Rotterdam (MEC-2012-140). Writ-
ten informed consent was obtained from all participants
or their legal guardians. Parent-child trio-based WGS of
a proband with metopic synostosis and ID (subject 3 in
Table 1) identified a de novo c.88G>A transition in CDK8;710 The American Journal of Human Genetics 104, 709–720, April 4,this change leads to the prediction of a heterozygous
p.Gly30Ser substitution. The position of this substitution,
at an almost invariant residue within the highly conserved
glycine-rich loop of the kinase domain,9 and in which
pathogenic mutations were previously identified in other
protein kinases,22,57 led us to seek evidence for additional
pathogenic variants in CDK8 through GeneMatcher
exchange10 and from the Deciphering Developmental Dis-
orders (DDD) research study.11 The DDD study has UK
research ethics committee (REC) approval (10/H0305/83,
granted by the Cambridge South REC, and GEN/284/12
granted by the Republic of Ireland REC). Details of the
methodology we used to identify each mutation (whole-
exome sequencing [WES] in every instance except the
original index subject) are provided in the Supplemental
Material and Methods. By these means, we identified a
further 11 unrelated individuals harboring eight different
nucleotide substitutions within CDK8; one substitution
(c.185C>T encoding p.Ser62Leu) was present in five
subjects (Figure 2A and Table 1). All CDK8 variants were
constitutionally absent from the ExAC and gnomAD data-
bases of common variation (accessed November 2018).12
CDK8 is a gene that comprises 13 exons; it is located
at chromosomal region 13q12.13 and encodes a major
isoform of 464 amino acids. All seven unique substitu-
tions, and three of five instances of p.Ser62Leu, arose
de novo from unaffected parents who had correct paternity
confirmed either by comparison of trio-WES or WGS
data or by microsatellite analysis; paternal samples were
unavailable in the remaining two cases (the recurrence of
the c.185C>T transition is likely to be explained by its
position in a hypermutable CpG dinucleotide). The eight
substituted amino acids are all located within the kinase
domain, which extends between amino acids 21–335
(Figure 2B), and they are invariant in a wide range of verte-
brate CDK8 orthologs, as well as in the human paralog
CDK19; in six cases, this invariance extends to the inverte-
brates Drosophila, Aedes, and Caenorhabditis (Figure 2C).
MutationTaster predicted all eight substitutions to be
disease-causing, and SIFT and PolyPhen-2 predicted all to2019
Table 1. Clinical Features of Subjects with CDK8 Mutations
Subject # 1 2 3 4 5 6 7 8 9 10 11 12
Gender f m m f m f m m f m f m
Age (years) 9 2.9 8 7.6 0.1 0.8 16.7 12.7 6.8 5.4 12 3.5
Mutation c.79G>C c.85C>G c.88G>A c.185C>T c.185C>T c.185C>T c.185C>T c.185C>T c.291T>G c.533G>A c.578T>G c.669A>G
Substitution p.Val27Leu p.Arg29Gly p.Gly30Ser p.Ser62Leu p.Ser62Leu p.Ser62Leu p.Ser62Leu p.Ser62Leu p.Phe97Leu p.Arg178Gln p.Val193Gly p.Ile223Met
De novo yes yes yes yes yes yes NA NA yes yes yes yes
Facial
dysmorphism
þ þ þ þ þ þ þ þ  þ þ þ
Hypotonia,
motor delay,
and/or walking
difficulty
þ þ (axial) þ þ NA þ (axial) þ (bilateral
pes planus
surgery)
þ þ þ þ þ
Brain MRI or CT normal thin corpus
callosum
normal ACC NA ACC NA ACC non-specific NA normal NA
Ophthalmic:
ptosis
þ          þ 
Strabismus þ þ þ     þ    
Myopia þ þ  þ   þ (severe) þ   þ 
Impaired vision þ      þ     
Sensorineural
hearing loss
moderate moderate   NA    severe
(unilateral)
NA (glue ear) 
Intellectual
disability
mild (SEN
school)
moderate
to severe
moderate to
severe (SEN
school)
moderate NA NA; moderate
motor delay
mild to
moderate
(SEN school)
moderate
(SEN school)
moderate moderate mild
(normal
school)
NA; moderate
motor delay
Behavioral
disorder
ADHD  ASD, ADHD,
sleep disorder
ADHD,
sleep
disorder
NA NA ASD ASD, ADHD ASD happy
disposition
attention
seeking,
volatile
ASD
Epilepsy       complex
partial
 general
and focal
  
Feeding
difficulties
infancy
only
gastrostomy-
fed
congenital pyloric
stenosis
previous
gastrostomy
NA  reflux reflux,
regurgitation
reflux,
episodic
vomiting
 episodic
vomiting

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712 The American Journal of Human Genetics 104, 709–720, April 4,be damaging with the exception of the c.291T>G
(p.Phe97Leu) variant (Table S1). CDK8 is intolerant to
missense variants (z ¼ 3.81, observed/expected ratio ¼
0.34; gnomAD database)12 and exhibits high constraint
throughout the protein.13 On the basis of the DOMINO
algorithm, CDK8 was predicted to be among the top
candidate genes for which mutations are likely to manifest
with a dominant pattern of inheritance.14 The clustering
of multiple de novo substitutions localized to a single,
highly conserved domain of the protein provides a strong
pathogenicity signature, as has been described for several
other genes including the cyclin-dependent kinase
(CDK)-encoding CDK13.11,15,16
We assessed the phenotypes of the 12 subjects, seven
males and five females aged 0.1–16.7 years at the last clin-
ical assessment, with CDK8 substitutions by using a stan-
dardized spreadsheet-based questionnaire (summarized in
Table 1; full details can be found in Table S2, and case
reports can be found in the Supplemental Note). Most
affected children were born after unremarkable pregnan-
cies, at or near term, with a birth weight within the normal
range, and they did not require neonatal resuscitation,
although around half required hospitalization after birth
because of jaundice, seizures, laryngomalacia, or cardiac
problems. More consistent difficulties emerged in early in-
fancy: hypotonia (noted in 11/12 subjects) was frequently
evident, and it later manifested as motor delay and some-
times persistent problems in walking. Mild to moderate
developmental delay was universal, and older children
had ID which ranged from mild (two cases) to moderate–
severe (two cases); most were in the moderate range (five
cases). Most children attended schools for special educa-
tional needs, but one had mainstream education. Behav-
ioral symptoms were prominent: seven of ten of the older
individuals had formal diagnoses of autism spectrum disor-
der (ASD) and/or attention deficit hyperactivity disorder
(ADHD). The head circumference was normal except in
one subject, who had mild macrocephaly (þ2.21 standard
deviations [SD]); magnetic resonance imaging (MRI) of the
brain showed agenesis or thinning of the corpus callosum
in four subjects, including the macrocephalic individual.
Two individuals had seizures, but brain imaging was either
normal or was not available. Three individuals had moder-
ate-severe sensorineural hearing loss; ophthalmological
abnormalities were frequent, including myopia (n ¼ 6),
eyelid ptosis (n ¼ 2), and/or strabismus (n ¼ 4), and these
were associated with marked visual impairment in two
children. Congenital heart defects (CHDs) were present
in six of the twelve subjects; the defects were classified17
as left ventricular obstruction (n ¼ 3), conotruncal defects
(n ¼ 1), and other (n ¼ 2). Present congenital gastrointes-
tinal problems were ano-rectal abnormalities (n ¼ 2) and
pyloric stenosis (n ¼ 1); two additional infants required
feeding via gastrostomy tube. In later childhood, gastro-
esophageal reflux or episodic vomiting were significant
management issues in four individuals. Facial dysmor-
phism was identified in 11 subjects; this was not2019
Figure 2. Mutations in CDK8 and Conservation of Substituted Residues
(A) Localization of mutations (in red) in a schematic representation of human CDK8 (exon numbering on GenBank: NM_001260.2).
(B) A cartoon of the humanCDK8 (based onUniProt: P49336) showing the location of the protein kinase domain (21–335; gray box) and
the eight different CDK8 substitutions identified in this work (below, in red). Note that the p.Ser62Leu substitution was identified in five
unrelated subjects. Relevant functional elements are depicted in dark boxes. Note the Gly-rich loop (27–35); Lys52, a catalytic residue
that interacts with the triphosphate of ATP in the active site; Asp151 within the conserved His-Arg-Asp (HRD) motif (at the catalytic
loop), which is directly involved in catalysis; and Asp173, which is included in the Asp-Met-Gly (DMG)motif (at the activation segment)
required for chelation of the magnesium ion involved in the catalysis. Substitution of Asp173 is widely used as a catalytically inactive
kinase-dead form of CDK8 (p.Asp173Ala).
(C) A multiple-protein sequence alignment of CDK8 and CDK19 at the positions of the identified substitutions in CDK8. Abbreviations
are as follows: Hs¼ human,Mm¼mouse, Xt¼western clawed frog, Dr¼ zebrafish, Dm¼ fruit fly, Ae¼ yellow fevermosquito, and Ce¼
nematodeworm. The positions of the CDK8 de novomissense variants are indicatedwith a red arrow at the top of the sequences. Black- or
gray-shaded amino acids indicate identical or similar residues compared to the human CDK8 sequence, respectively. Below the align-
ments, an asterisk (*) indicates positions that have a single, fully conserved residue, whereas a colon (:) indicates conservation between
groups of similar properties. Additional relevant features present in these sequences (Gly-rich loop, DMGmotif, and the Asp173 residue,
mutated in the kinase-dead mutant) are also depicted.characteristic, although arched eyebrows, epicanthic folds,
prominent eyes, a prominent nasal tip or long columella, a
long philtrum, wide or open-mouth posture, prognathism,
and low set and prominent ears were highlighted in two or
more subjects (Figure 3 and Table S2). The subjects’ stature
was within the normal range except in one individual,
who hadmild short stature (2.53 SD). Apart from the me-
topic synostosis present in the index individual, no other
individuals had craniosynostosis.
We assessed the probable effects of the eight individual
amino acid substitutions on the CDK8 kinase domain
by examining available protein structures (Figure 4). Three
of the substitutions (c.79G>C [p.Val27Leu], c.85C>G
[p.Arg29Gly], and p.Gly30Ser) are clustered in the Gly-
rich loop (amino acids 27–35), a highly conserved pro-The Ametein-kinase motif with a critical role in ATP binding
and in the phosphoryl-transfer reaction.21–23 Substitutions
within this motif affect kinase activity and, in other
kinases, have been described as pathogenic mutations
responsible for various congenital disorders.15,22,24,25
Within the three-dimensional structure, all CDK8 substitu-
tions either affect amino acids surrounding the ATP-bind-
ing pocket (Figure 4B) or are in contact with key functional
amino acids; for example, the p.Ile223 residue is not
directly part of the ATP-binding site but is within interact-
ing distance of p.Lys153, which directly binds to the ATP
phosphate in the input structural model. The recurrently
mutated p.Ser62 residue is located in the aC-helix,26
the conformation and interactions of which are impor-
tant for CDK8 activity.27 Two substitutions, c.533G>Arican Journal of Human Genetics 104, 709–720, April 4, 2019 713
Figure 3. Clinical Pictures of Subjects with CDK8 Mutations
Subjects (left to right): 1 (c.79G>C [p.Val27Leu]) aged 16 months, 3 (c.88G>A [p.Gly30Ser]) aged 4 years (postoperative after surgery to
correct metopic synostosis), 4 (c.185C>T [p.Ser62Leu]) aged 9 years, 10 (c.533G>A [p.Arg178Gln]) aged 9 years, and 11 (c.578T>G
[p.Val193Gly]) aged 2.5 years.(p.Arg178Gln) and c.578T>G (p.Val193Gly), affect amino
acids located in the activation segment,26 which interacts
with other key amino acids (Figure 4B). One of the substi-
tutions (p.Phe97Leu) affects the ‘‘gatekeeper’’ p.Phe97 of
CDK8. Mutations in the gatekeeper residue of kinases
have emerged as a key mechanism by which cancer cells
develop resistance to treatment,28 highlighting the impor-
tance of the gatekeeper residue controlling the back cavity
of the ATP site.29
To gain further insights into the effects of the muta-
tions, we conducted molecular-dynamics simulations for
wild-type (WT) and two selected CDK8 substitutions,
p.Ser62Leu, and p.Arg178Gln, in complex with cyclin C
and in the presence of ATP. The overall CDK8 protein
structure and organization was predicted to be unchanged
in the mutant models compared to in the WT. However,
we found that in addition to impacting the ATP-binding
site, the mutants were also predicted to induce pro-
nounced structural changes in the substrate-binding site
(Figure 4C). In particular, the substrate-binding site of
the WT CDK8 protein can adopt more open conforma-
tions than its mutated counterparts, potentially allowing
substrates to bind more closely in the vicinity of ATP in
the WT protein.
To determine whether the CDK8 kinase domain substi-
tutions had caused structural changes and/or affected
the ability to bind ATP, we purified CDK8 kinase Modules
that were isolated from cells by immunoprecipitation after
the expression of WT or mutant-tagged-CDK8 (Figures 5A
and S1), and we recorded protein-melting curves in the
absence or presence of ATP (Figure 5B). In the absence of
ATP, the thermal stability of mutant proteins ranged
from indistinguishable to increased in comparison to the
WT protein. Moreover, the stability of most mutant pro-
teins was increased by the addition of ATP, in some cases
to a greater extent than occurred in the WT protein.
Together these results suggest that none of the substitu-
tions cause gross mis-folding of the protein, and most or
all are still able to bind ATP.
Finally, we investigated how the CDK8 substitutions
affected the kinase activity by measuring phosphorylation
of one of its well-validated targets: p.Ser727, of the human714 The American Journal of Human Genetics 104, 709–720, April 4,transcription factor STAT1.30–34 We used a CRISPR-Cas9-
engineered human cell line (SW620 colorectal carcinoma
cells) that lacks both CDK8 and CDK19 (M.J. Ortiz-Ruiz
et al., Cancer Res., abstract). These cells exhibited baseline
STAT1-Ser727 (pSTAT1) phosphorylation that was substan-
tially increased when WT CDK8 was transiently re-ex-
pressed (Figure 6). We performed site-directed mutagenesis
to introduce the eight observed variants into CDK8 cDNA
(Supplemental Material and Methods), which we trans-
fected into the CDK8 and CDK19 CRISPR double-knockout
cells. We observed that the cellular levels of pSTAT1 were
reduced to a statistically significant extent, compared to
WT, in all mutant-transfected cells (Figure 6). For most mu-
tants, the reduction in kinase activity was similar to that in
the catalytically inactive CDK8 kinase-dead (p.Asp173Ala)
mutant we used as a control, but in two mutants (p.Phe97-
Leu and [c.669A>G] p.Ile223Met), an intermediate level of
phosphorylation (63% and 51% in comparison to the
WT, respectively), was observed.
Collectively, our genetic and functional assessments
provide strong evidence for a previously unrecognized (to
our knowledge) clinical disorder caused by heterozygous
missense substitutions located in the kinase domain of
CDK8. All eight distinct mutations were shown to have
arisen de novo from unaffected parents (Table 1) and ex-
hibited a similar combination of molecular characteristics.
All clustered within the kinase domain (Figure 2) and were
concentrated around the ATP binding pocket (Figure 4);
none was associated with gross protein instability, and all
retained the ability to bind ATP (Figure 5). Finally, all ex-
hibited attenuated kinase activity in a previously validated
assay of STAT1-phosphorylation, although the magnitude
of the effect was diminished for two substitutions
(Figure 6), suggesting partial retention of activity in those
cases. Of note, the CDK8 mutant proteins maintained
their ability to bind cyclin C, similar to the ability of the
kinase-dead mutant (Figures 5A and S1, and as previously
described).35 The CDK8 kinase-dead mutant was previ-
ously shown to form a stable Module, although the inac-
tive kinase was unable to phosphorylate its targets.35,36
Concordant with these molecular observations was a
relatively consistent phenotypic presentation (Figure 3,2019
Figure 4. Location and Effect of CDK8
Substitutions on the Protein Structure
(A) Overall structure of CDK8 (light gray)
in complex with cyclin C (dark gray).
ATP (blue) was modeled into the CDK8
DMG-in crystal structure (PDB: 4F7S)18
using aligned CDK9 (PDB 3BLQ).19 Re-
gions not previously resolved in the crystal
structure have been modeled using Molec-
ular Operating Environment (MOE).20
(B) Amagnified view of the catalytic region
of the CDK8 kinase domain. The Mg2þ is
shown as a green sphere. Amino acids
at which mutations have been identified
are colored in orange (except Ser62 in red
and Arg178 in yellow), and relevant,
potential interaction partners in the input
structure are shown as sticks. Ile223 is in
close proximity (double-headed arrow) to
the Lys153 involved in interaction with
ATP-phosphate. Arg178 forms a hydrogen
bond with Tyr32 (Gly-rich loop) and inter-
acts ionically with the catalytic Asp151.
(C) A magnified overlay of the wild-type
(WT) and mutant molecular-dynamics
simulations of CDK8 (light gray) in com-
plex with cyclin C (dark gray) in the pres-
ence of ATP (blue spheres). The areas dis-
playing the most pronounced structural
differences within the substrate binding
site are colored (blue: WT, red: p.Ser62Leu,
and yellow: p.Arg178Gln).Table 1, Supplemental Case Reports, and Table S2). Hypo-
tonia was usually evident in infancy and, in children old
enough for assessment, learning disability was universal
and most commonly classified as moderate; most but
not all children were attending schools for special
educational needs. Associated behavioral problems, which
were frequent and added to the management issues for
these children, included formal diagnoses of ASD and
ADHD, sleep disorders, and episodic vomiting. Dysmor-
phic facial features, including arched eyebrows, a bulbous
or upturned nose, and hypotonic facies, were frequent;
however, these do not constitute a consistent or easily
recognizable phenotype. Six of 12 subjects had congenital
heart malformations, including at least three requiring
corrective surgery. Additional medically significant fea-
tures are documented in Table 1. The high frequency
of diagnosis of ASD, ADHD, and CHD in these chil-
dren is of note because CDK8 mutations have not
previously been highlighted in genetic screens of those
disorders;17,37 this might be because the target size for
mutations of CDK8 (missense substitutions surrounding
the ATP-binding pocket) is relatively small. Although the
mutation in our index subject, who had metopic synosto-
sis, was originally identified in a genetic study of craniosy-
nostosis, none of the 11 other subjects identified had thisThe American Journal of Humanphenotype. It is unclear whether the
co-occurrence of the mutation and
craniosynostosis is causally linked(potentially through the adverse effect of the mutation
on brain development)38 or is coincidental.
Inmore than two decades since CDK8was first identified
in independent studies of the yeast Saccharomyces cerevisiae
(from screens for the stabilization of meiotic mRNAs
[Ume5]39 and suppression of an RNA polymerase II
C-terminal domain mutation [Srb10]),40 a large literature
has accumulated about its functions.5,41 As described
above and illustrated in Figure 1, CDK8 encodes a kinase
component of the Module, a four-subunit complex that
binds to the Mediator and regulates its activity. Many
fundamental uncertainties remain about its function, for
example how the association and dissociation of the Mod-
ule with the Mediator is regulated, how the Module regu-
lates gene expression both positively and negatively, and
the extent to which kinase activity per se is required for
these functions.2 Previous studies of human CDK8 have
mostly focused on its potential as a therapeutic target in
cancer, on the basis of the observation that amplifications
of CDK8 are frequent in colon cancer.42 Although effective
CDK8 inhibitors have been developed, to date they have
exhibited unacceptable toxicity.31,32 This toxicity might
reflect the essential function of CDK8 for normal develop-
ment, as shown by the pre-implantation lethality of ho-
mozygous-null Cdk8mutations in the mouse; importantlyGenetics 104, 709–720, April 4, 2019 715
Figure 5. Immunoprecipitation of CDK8
and Thermal Stability Assay
(A) Lysates from HEK293T cells transiently
transfected with Myc-FLAG-tagged wild-
type (WT) or mutant CDK8 constructs
were used for immunoprecipitation with
anti-FLAG antibody or mouse IgG isotype
control antibody. The immunocomplexes
were purified with protein G magnetic
beads. CDK8 was released by adding
FLAG peptide, and an aliquot of the
eluted fraction was saved for immunoblot
analysis with anti-Myc or anti-cyclin C
(CycC) antibodies.
(B) A thermal stability assay of the eluted
fractions incubated in the absence or pres-
ence of ATP and heated individually at
different temperatures (gradient between
50–82C). Virtual blot views of results
for WT and the mutants are shown. For
each CDK8 construct, the red arrowhead
indicates 50% reduction of the CDK8
signal compared to the signal at the lowest
temperature.in relation to the discussion below, heterozygous animals
were reported to be normal and fertile.43
If one focuses on the developmental role of CDK8, our
observations show that although a single WT CDK8 allele
is sufficient for survival, heterozygosity for a mutant allele
that encodes a missense substitution of the kinase domain
causes pleiotropic developmental abnormalities. Broadly
speaking, heterozygous mutations might be associated
with abnormal phenotypes through one of three mecha-
nisms: haploinsufficiency, gain of function, and domi-
nant-negative activity.44 When haploinsufficiency occurs,
many mutations are expected to be either truncating or
partial or whole-gene deletions. Deletions involving
CDK8 are very rare, and those recorded involve many
other genes, so they are essentially uninformative.
Although our gene-matching methods would not detect
deletions, they were unbiased with regard to the nature
of the intragenic mutation. It was previously reported
that 381 of 706 de novo mutations in haploinsufficient
genes were truncating,11 so the finding that 11/11
(excluding the index subject) intragenic nucleotide substi-
tutions encode missense changes diverges significantly
from a haploinsufficiency pattern (p ¼ 0.0004). Moreover,
human CDK8 is only moderately constrained to loss of
function (probability that the gene is intolerant to a loss
of function (LoF) mutation (pLI) ¼ 0.38, gnomAD data-
base); it has six (out of 250,000) bona fide truncating
alleles listed in gnomAD, suggesting that such alleles
exist at low frequency in the normal population. Overall,
haploinsufficiency appears unlikely to be the underlying716 The American Journal of Human Genetics 104, 709–720, April 4, 2019mechanism that explains the CDK8-
mutation-associated phenotype.
Instead, our experimental observa-
tions indicate that the mutations
retain ATP binding yet lose ordiminish the ability to phosphorylate a well-established
substrate, STAT1. This might result from reduced ATP
catalysis and phosphoryl-transfer and/or altered substrate
binding resulting from reduced accessibility of the sub-
strate-binding site predicted by the dynamic modeling
(Figure 4). Notably, CDK8 (together with its paralog
CDK19) are the only components of the Module with cat-
alytic activity, so we predict that up to 50% of CDK8 mod-
ules could be present in a kinase-inactive, non-productive
state. The consequence of this would then depend on the
extent to which supply of the catalytically-active Module
was rate-limiting to key cellular processes in particular
developmental contexts. The notion that the supply of
active Modules might frequently be limiting is supported
by the observation that all six other genes encoding com-
ponents of the human Module (CCNC, CDK19, MED12,
MED12L, MED13, and MED13L) exhibit very strong
constraint against loss-of-function variation (pLI ¼ 1,
observed/expected scores 0–0.11), indicating that reduc-
tion of any Module component by 50% impairs survival
(by contrast, only three of 26 genes encoding other com-
ponents of the Mediator exhibit pLI ¼ 1; Table S3).
Together, these observations currently support a domi-
nant-negative mechanism of pathogenesis for CDK8
substitutions. Similar patterns of localized missense sub-
stitutions have been highlighted as a signature of domi-
nant-negative activity, including in the kinase domain
of another cyclin-dependent kinase, CDK13.15,16 More-
over, overexpression of the kinase-dead mutants of
different CDKs (CDK1, CDK2, CDK3, or CDK9) in human
Figure 6. Effect of CDK8 Substitutions on STAT1-Ser727 Phosphorylation
SW620 CDK8 and CDK19 double-knockout cells were transiently transfected with FLAG-tagged wild-type (WT) or mutant CDK8 con-
structs, and the cellular levels of pSTAT1-Ser727 were determined as a readout of CDK8 activity. The CDK8 kinase-dead (p.Asp173Ala)
mutant was used as a control for defective kinase activity. Whole-cell lysates from non-transfected cells (E lane) or from transfected cells
were collected, and equal amounts of total protein were subjected to immunoblotting with anti-phospho-STAT1-Ser727 and anti-STAT1
(total) antibodies. Anti-FLAG was used to detect the overexpressed CDK8 constructs, and GAPDHwas used as loading control. Represen-
tative blots are shown in the two left panels. For the quantification (right panel), the relative intensities of the bands were taken as a ratio
of the phosphorylated STAT1-Ser727 (pSTAT1) over the total amount of STAT1 (STAT1) and then plotted against the WT, which
was normalized to one, for each individual blot. The values shown represent means 5 SEM from five independent experiments. The
results were compared to WT and analyzed by one-way ANOVA with Dunnett’s multiple-comparisons test; * p % 0.05, ** p % 0.01,
and *** p% 0.001.cells was previously observed to act by dominant-negative
mechanisms.45–47 We explored the mechanism directly
by mixing equal amounts of the WT and p.Ser62Leu
CDK8 constructs and measuring STAT1 phosphorylation,
but the observed reduction in phosphorylation in mixed
samples did not obviously deviate from a linear response
(data not shown); hence, further experiments will be
required to support or refute the dominant-negative
hypothesis.
Previous observations that mutations in MED12
(X-linked; mostly hemizygous) and MED13L (heterozy-
gous) were associated with generally similar phenotypes,
including ID, hypotonia, and other congenital anoma-
lies,6–8,48 led to the coining of a so-called ‘‘mediatorpathy’’
phenotype.49 More recently, heterozygous mutations
in MED13 were also considered to fit this pattern.9
Interestingly, in the case of MED12, it was demonstrated
experimentally that the substitutions p.Arg961Trp and
p.Asn1007Ser (causing FG and Lujan syndromes,
respectively), exhibit impaired recruitment of CDK8 onto
GLI3-target gene promoters, leading to hyperactivated
GLI3-dependent SHH signaling.50 Here, we find that the
major clinical features (including moderate ID, hypotonia,
ASD, ADHD, and CHD) associated with CDK8 muta-
tions again show substantial phenotypic overlap, lending
further support to the general concept of a Module-related
syndrome. By contrast, relatively fewer (to date, up to four
replicated: MED17, MED20, MED23, and MED25) muta-
tions in the other 26 non-Module components of the
Mediator have been described; bi-allelic mutations in
MED17 or MED20 (both members of the Mediator’s
Head) produce progressive cerebral and/or cerebellar
atrophy, whereas bi-allelic mutations in MED23 or
MED25 cause syndromic or non-syndromic ID (summa-
rized in Table S3).The AmeIn summary, therefore, our observations support the
proposed clustering of developmental disorders related to
perturbed function of the Module (‘‘Mediator kinase mod-
ulopathy’’). Given the pleiotropic actions of the Module,
many mechanisms, including defects in key develop-
mental signaling pathways, might lead to these pathol-
ogies. For example, the severe developmental defects iden-
tified in embryos with Med12 hypomorphic mutations are
produced by impairment of the canonical and Wnt/PCP
signaling pathways;51 analogously, CDK8 has a pivotal
role as a regulator of several additional signaling pathways,
includingWNT, TGFb/BMP, STAT1, SHH, and NOTCH.52,53
Thus, a disruption of the proper activity of CDK8 could
modify any of these developmental signaling networks.
Although the idea of a Mediator kinase modulopathy
as a pathogenic entity is attractive, several cautions are
necessary. Genetic evidence from Drosophila formally
demonstrates the non-equivalence of different Module
components, on the basis of differences in the respective
phenotypes when comparing mosaic knockouts for a
Cdk8-Ccnc pair compared with a Med12-Med13 pair.54
This situation is compounded for vertebrates, in which
paralogous pairs exist for three of the four Module sub-
units. Indeed, the single described disruption (caused by
a chromosomal inversion) of the CDK8 paralog CDK19
was associated with a different phenotype that comprised
microcephaly, congenital bilateral falciform retinal folds,
nystagmus, and learning disability;55 however, the func-
tions of CDK8 and CDK19 are known to be divergent.56
Finally, it remains uncertain to what extent, and in which
circumstances, Module activity might be kinase-indepen-
dent because these functions would likely be unaffected
by the mutations described here.2 Further work on the
structure and function of the Mediator will doubtless
shed light on these issues.rican Journal of Human Genetics 104, 709–720, April 4, 2019 717
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